Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 38Neoplasms 19Breast Neoplasms 9Head and Neck Neoplasms 5Colorectal Neoplasms 3Neoplasm Metastasis 2Carcinoma, Squamous Cell 2Adenocarcinoma 2Urologic Neoplasms 1Stomach Neoplasms 1Squamous Non-small Cell Lung Cancer 1Solid Tumors 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neuroectodermal Tumors 1NSCLC Harboring NRG1 Fusion 1Lung Neoplasms 1Glioma 1Glioblastoma 1Colonic Neoplasms 1Advanced Solid Tumors 1

Interventions

Paclitaxel 3Carboplatin 3pembrolizumab 1necitumumab 1anlotinib 1Gemcitabine 1Cisplatin 1Afatinib 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Squamous Non-small Cell Lung Cancer × Afatinib × Clear all
NCT04552535 2022-01-11

A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the Lung

Boehringer Ingelheim

Completed
200 enrolled 18 charts
Thoracic

Squamous Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡